Glow in the dark fluid:Nanoparticles and DNA-binding antibodies as priming agents for liquid biopsies  

照亮黑液的光芒:纳米颗粒和DNA结合抗体作为引发剂助力液体活检

作　　者：Yi Zhang Wanlu Zhang Yinghao Zhi Hongwei Sun Min Wu Yongye Huang 张怡;张琬璐;支英豪;孙宏伟;吴敏;黄永业

机构地区：[1]Key Laboratory of Bioresource Research and Development of Liaoning Province,College of Life and Health Sciences,Northeastern University,Shenyang 110169,China [2]Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University,Wenzhou 325000,China [3]Department of Hepatobiliary Surgery,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325035,China [4]Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325000,China

出　　处：《Science Bulletin》2024年第22期3474-3477,共4页科学通报（英文版）

基　　金：supported by the Construction Project of Liaoning Provincial Key Laboratory;China(2022JH13/10200026);Fund of the Affiliated Xiangshan Hospital of Wenzhou Medical University;Wenzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University;Wenzhou;Department of Hepatobiliary Surgery;The First Affiliated Hospital of Wenzhou Medical University;Wenzhou Institute University of Chinese Academy of Sciences。

摘　　要：Current challenges and opportunities for liquid biopsies.Liquid biopsies serve as an indispensable clinical diagnostic tool when traditional biopsies are difficult to obtain or yield inadequate samples for genetic monitoring.However,achieving optimal sensitivity and stability poses a significant challenge due to the difficulty of detecting low levels of plasmatic cell-free DNA(cfDNA).Recently,Dr.Carmen Martin-Alonso and colleagues[1]reported that priming agents,consisting of nanoparticles and DNA-binding monoclonal antibodies(mAbs),could significantly improve the sensitivity and robustness of liquid biopsies.The innovative use of priming agents promises improved liquid biopsies across various clinical applications by enhancing efficacy,accuracy,and depth of ex vivo sequencing and analysis.Importantly,it reduces the need to draw large blood volumes from patients or perform extensive plasma exchange to obtain sufficient cfDNA(Table 1).

关 键 词：ANTIBODIES clinical LIQUID 

分 类 号：R318[医药卫生—生物医学工程] TB383.1[医药卫生—基础医学]